Personalized care. One $109/month membership. Explore membership
Weight Management
Original editorial photograph of a hand holding an unmarked tablet; not an actual Foundayo tablet
LEXA HEALTH / WEIGHT MANAGEMENT

Foundayo tablets

Orforglipron

A non-peptide oral GLP-1 option taken daily, with or without food.

Administration
Daily oral tablet
Clinical evaluation
Required before prescribing
Membership
$109/month · Medication billed separately
Get Started

Availability and suitability depend on individual evaluation. Membership does not guarantee a prescription.

Understanding Foundayo tablets

Foundayo is an FDA-approved daily oral GLP-1 receptor agonist for long-term weight management in eligible adults. Its active ingredient, orforglipron, is a small molecule rather than a peptide.

How it works

Orforglipron activates the GLP-1 receptor to help regulate appetite and food intake. Its non-peptide structure allows oral administration without the fasting and water restrictions required for oral semaglutide.

How it is administered

Take one tablet once daily, with or without food. Swallow whole; do not break, crush or chew, and do not take more than one tablet per day. Your clinician increases the dose gradually based on response and tolerance. The 17.2 mg maximum dose used in the calculator is not a starting dose.

Clinical research & results

In ATTAIN-1 (label Trial 1), Foundayo 17.2 mg averaged 11.1% weight reduction at 72 weeks, compared with 2.1% with placebo, in the intention-to-treat analysis. The study enrolled adults without diabetes. Its trial formulations and approved doses are described in the label; the calculator uses the approved 17.2 mg dose, not the investigational dose naming.

These are separate trials, not a direct comparison between medicines. Study averages do not establish which medicine is best for you.

Foundayo full prescribing information
THE RESEARCH, IN CONTEXT

What could the study average look like?

An educational illustration of 11.1% weight reduction over 72 weeks.

ATTAIN-1 · Trial 1 · 17.2 mg daily

Adults with obesity (BMI ≥30), or overweight (BMI ≥27) with at least one weight-related condition, without diabetes. Participants also received reduced-calorie diet and physical-activity support.

lbs
100 lbs500 lbs
Illustrative pounds lost≈ 28 lbs
Illustrative remaining weight≈ 222 lbs

11.1% average reduction · 72 weeks

These figures represent average results observed in clinical trials and are provided for educational purposes only. Individual results vary. Actual outcomes depend on individual health factors, treatment response, adherence, and other considerations. Results are not guaranteed. Medication is prescribed only following an individualized clinical evaluation.

Common side effects

Common side effects include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache and fatigue. Report persistent symptoms and problems staying hydrated to your care team.

Safety & important considerations

  • Do not use with a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or a serious allergy to the medication. These products carry a boxed thyroid C-cell tumor warning; the risk in humans is unknown.
  • Serious risks include pancreatitis, gallbladder problems, dehydration-related kidney injury and severe digestive symptoms. These medicines are not recommended in severe gastroparesis. Seek urgent care for persistent severe abdominal pain, serious allergic symptoms, or sudden vision changes.
  • Tell your clinician about all medicines, diabetes-related eye disease, planned anesthesia or deep sedation, and pregnancy plans. Low blood sugar risk can increase with insulin or sulfonylureas. Do not combine with other GLP-1 medicines; your clinician reviews interactions and suitability.
  • Discontinue when pregnancy is recognized and discuss pregnancy plans with your clinician. Oral contraceptive users should switch to a non-oral method or add a barrier method for 30 days after starting and for 30 days after each dose increase. Foundayo has specific interactions, including with strong CYP3A4 inhibitors and certain statins; your clinician must review your medication list.

This is a summary, not a complete list of risks or instructions. Read the full prescribing information and Medication Guide and speak with your clinician.

Read official safety information
YOUR QUESTIONS

More about Foundayo tablets

Do I need to fast before taking Foundayo?

The label allows Foundayo with or without food. It does not require the empty-stomach morning routine used for Wegovy tablets.

Is Foundayo oral semaglutide?

No. Foundayo contains orforglipron, a non-peptide small molecule. Wegovy contains semaglutide. They have different dosing and administration instructions.

Is the tablet photograph the actual product?

No. It is original editorial photography of an unmarked tablet, not a depiction of an actual Foundayo tablet. The official label and dispensed packaging identify the product.

Care begins with a conversation.

Explore a personalized plan with Lexa Health.

Get Started